US5725863A - Polypeptides useful in prevention of chlamydia infection - Google Patents

Polypeptides useful in prevention of chlamydia infection Download PDF

Info

Publication number
US5725863A
US5725863A US07/756,346 US75634691A US5725863A US 5725863 A US5725863 A US 5725863A US 75634691 A US75634691 A US 75634691A US 5725863 A US5725863 A US 5725863A
Authority
US
United States
Prior art keywords
chlamydia
vaccine
polypeptide
kilodaltons
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US07/756,346
Inventor
Eddie K. Daniels
Neal E. Woollen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Agriculture USDA
Original Assignee
US Department of Agriculture USDA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Agriculture USDA filed Critical US Department of Agriculture USDA
Priority to US07/756,346 priority Critical patent/US5725863A/en
Assigned to UNITED STATES OF AMERICA, THE, AS REPRESENTED BY THE DEPARTMENT OF AGRICULTURE reassignment UNITED STATES OF AMERICA, THE, AS REPRESENTED BY THE DEPARTMENT OF AGRICULTURE ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: DANIELS, EDDIE K., WOOLLEN, NEAL E.
Application granted granted Critical
Publication of US5725863A publication Critical patent/US5725863A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Definitions

  • This invention relates generally to vaccines for veterinary use.
  • it relates to Chlamydia vaccines useful for prevention and treatment of disease processes created or induced by Chlamydia organisms.
  • this invention relates to essentially pure polypeptides of Chlamydia psittaci strain DD-34 in a pharmaceutically acceptable carrier and the use of this composition as a vaccine for a number of Chlamydia strains.
  • Chlamydia are unique organisms that infect a susceptible host by an infectious particle called an elementary body.
  • An elementary body is small, approximately (200-300 nm) and is resistant to environmental factors. The organism attaches itself to the host cell and is ingested by a phagocytic process.
  • Schachter, J. Overview of Chlamydia trachomatis Infection and Requirements for a Vaccine, Rev. Inf. Dis. 7:713 (1985).
  • Chlamydia are of medical and biological interest because of their unique interaction with eukaryotic host cells, and the diverse diseases they cause in man and animals.
  • Animals susceptible to Chlamydia psittaci infections are widely distributed in the animal kingdom, ranging from wild and domesticated birds and mammals to man. These infections have been identified as a cause of pneumonia, enteritis, encephalitis, conjunctivitis, and polyarthritis; abortions and genital disorders; and clinically unapparent infections.
  • Chlamydia psittaci is considered to be primarily a pathogen of animals other than man several strains have shown varying degrees of zoonotic potential.
  • Chlamydial infections are recognized in at least 130 species of birds and the transmission from birds to man is well documented.
  • Various strains of Chlamydia psittaci are well recognized as causing disease syndromes in a wide variety of mammalian species and Chlamydia psittaci infections in humans have been epidemiologically linked to many of these sources.
  • Fudge, A. M. Update on Chlamydiosis. Vet. Clin. of N. Amer. Small Animal Practice, 14(2):201-21 (March 1984).
  • Moran, R. Epidemiologic and Laboratory Observation of Chlamydia psittaci Infections in Pet Birds. Jour. of Amer. Vet. Med. Assn. 184(11):1372-4 (Jun. 1, 1984). Nagington, J. Psittacosis/Ornithosis in Cambridgeshire. 1975-1983. Jour. Hyg. Camb. 92:9-19.
  • Vaccines against chlamydia have been disclosed.
  • two proteins of molecular mass of 18,000 daltons and 31,000 daltons are known to be associated with infectious elementary bodies of C. trachomatis have been found to bind to eukaryotic cells. These proteins are thought to be of particular interest because the attachment of the pathogen to its host cell is critical to successful invasion of the elementary bodies.
  • Antibodies raised against these proteins possess neutralizing activity, which may indicate a protective role for such antibodies.
  • Purified 18 kilodalton C. trachomatis extra cellular binding protein substantially free of other C. trachomatis proteins in a pharmaceutically acceptable carrier and purified 31 kilodalton C. trachomatis extracellular binding protein substantially free of other C. trachomatis proteins in a pharmaceutically acceptable carrier have been disclosed as vaccines. EPA 0,293,079.
  • the polypeptide vaccine described in this application has shown, by an initial multiple challenge, to be highly protective against Chlamydia infection. Surprisingly, it was found that a 96 kilodalton polypeptide and certain associated polypeptides that includes the extracellular binding protein and other related proteins of ATCC strain DD-34 are highly antigenic and can provide protection from a variety of Chlamydia strains.
  • a 96 kilodalton polypeptide, of the Chlamydia psittaci strain DD-34 was isolated along with other polypeptides ranging in size from 40-140 kilodalton.
  • this invention is directed to a vaccine for treating patients to protect against a Chlamydia infection comprising administering an effective amount of a polypeptide as described herein above in a physiologically acceptable diluent.
  • This invention further relates to a subunit vaccine against Chlamydia psittaci strain DD-34, wherein the polypeptides are reactive with antibodies secreted by hybridoma ATCC no. HB10861.
  • the present invention relates principally to a 96 kilodalton polypeptide, and to other polypeptides ranging from about 40 to 140 kilodaltons that are useful, for immunization against Chlamydia.
  • polypeptides ranging from 40 to 140 kilodaltons of strain DD-34 were used.
  • the subunit vaccine may comprise the combination of the 42 and 96 kilodalton polypeptides and, in another embodiment the subunit vaccine may include only the 96 kilodalton polypeptide. It should be noted, however, that the molecular weights disclosed herein are not to be interpreted as absolute values.
  • the polypeptides of the present invention are capable of forming "neutralizing antibodies" i.e. antibodies that will protect against Chlamydia psittaci and Chlamydia trachomatis in a variety of animals.
  • the polypeptides have been found to be useful for immunizing against a bovine respiratory, DD-34, mouse pneumonitis, and guinea pig conjunctivitis strains of Chlamydia.
  • the present invention is also directed to methods of protecting a patient against contracting Chlamydia psittaci and Chlamydia trachomatis.
  • the active component of the vaccine according to the invention can be employed with a physiologically acceptable diluent (medium), e.g. phosphate buffered saline.
  • a physiologically acceptable diluent e.g. phosphate buffered saline.
  • the vaccine may possibly be administered by subcutaneous, intradermal, intranasally or intramuscular injection, or as a water additive. Frequency of administration will vary depending upon the vaccine.
  • the above described invention would afford protection to several species of animals such as mouse, guinea pig, cow and man. It is also expected to protect against several different biovars of Chlamydia, without the delayed type hypersensitivity reaction or anamnestic response reported with whole organism vaccines.
  • mice Three-month old female Balb/C mice were injected intraperitoneally with 0.2 ml of the elementary body-adjuvant solution. One injection was given weekly for a total of three injections. A fourth injection without RIBI adjuvant was given intraperitoneally four days before fusion.
  • the hyperimmunized spleen cells were fused with AG8 myeloma cells with the aid of polyethylene glycol. After four fusions and the production of approximately 1,600 hybridomas, 19 were identified as rapid growers. These 19 hybridomas were cloned when appropriate by limiting dilution.
  • Supernatants from the 19 hybridomas obtained in Example 1 were isotyped using an isotyping reagent kit (Hy Clone Laboratories, Logan, Utah) and subisotyped using a reagent kit (Calbiochem Corp., LaJolla, Calif.), according to the manufacturers' recommended protocols. Briefly, the supernatants were isotyped by coating 96-well microtiter plates with 100 ⁇ l of a plate coating solution containing 1% goat anti-mouse immunoglobulins. Excess solution was removed by tapping on absorbent paper before filling the wells with a phosphate-buffered saline-surfactant solution to reduce non-specific binding.
  • a plate coating solution containing 1% goat anti-mouse immunoglobulins was used to coat a 96-well microtiter plate.
  • the supernatants were diluted with phosphate-buffered saline-surfactant solution and added to the plate. After washing, typing antisera was placed in the wells for testing the supernatants, and phosphate-buffered saline-surfactant was used for negative controls.
  • a peroxidase conjugate was used followed by a 1% urea peroxide substrate and O-phenylene diamine as a chromophobe. The results of isotyping and subisotyping are reported in Table I, below.
  • Example 2 The hybridoma supernatants of Example 2 were further characterized by use of a mouse IgG, enzyme immunoassay, hybridoma screening kit according to the manufacturer's recommendations (Vector Laboratories, Burlingame, Calif.). Briefly, whole elementary bodies of C. psittaci strain DD-34 were diluted 1 to 250 in deionized distilled water and 100 ⁇ l was placed in each well of a 96-well microtiter plate (Midland Scientific, Inc., Omaha, Nebr.). Elementary bodies (ATCC No.
  • VR854 Strain DD-34) were diluted 1 to 10 in a solution containing 0.218 molar sucrose, 0.0038M KH 2 PO 4 , 0.0072M K 2 HPO 4 , and 0.0049M phosphate glutamate sucrose.
  • the phosphate glutamate sucrose solution had been autoclaved at 10 pound pressure for 10 minutes and the pH adjusted to 7.0 with 2N KOH prior to use.
  • Yolk sacs of 7-day-old specific pathogen-free chicken eggs (Spafus, Inc., Roanoke, Ill.) were injected with 0.4 ml of the dilution of 1 to 10 elementary bodies-phosphate glutamate sucrose solution.
  • Yolk sac membranes of all eggs that lived past three days were harvested on day seven, mixed with phosphate glutamate sucrose to make a 20% yolk sac membrane solution, homogenized and centrifuged at 300 ⁇ G for 10 minutes at 4° C.
  • the centrifugate contained three layers.
  • the middle layer containing the elementary bodies was removed with a pipette and purified through RENOGRAFIN 60 (Squibb, New Brunswick, N.J.) density gradients, consisting of 22 ml of 20% RENOGRAFIN on top of 5 ml of 50% RENOGRAFIN. These gradients were centrifuged at 63,500 ⁇ G for one hour at 4° C.
  • the elementary body fraction collected at the 50% RENOGRAFIN (Squibb) interface The elementary bodies were removed by drip fractionation and pelleted through calcium-magnesium-free phosphate-buffered saline by centrifuging at 49,200 ⁇ G for 20 minutes at 4° C. Each pellet was resuspended in 1 ml of calcium-magnesium-free phosphate-buffered saline and frozen at -70° C.
  • the plate was sealed with cellophane tape and placed on a shaker in a 37° C. incubator overnight.
  • Supernatants from each of the 19 hybridomas were diluted 1 to 250 and 100 ⁇ l of each was assayed in replicates of five.
  • the assay was done using a biotinylated anti-mouse IgG in phosphate-buffered saline containing 1% normal bovine serum, followed by an avidin-enzyme system with a 2,2'azino-di (3-ethyl benthiazolin-sulfate) substrate.
  • the results were read on a BIO-TEK EL-380 ELISA Reader at 405 nm (BIO-TEK, Winooski, Vt.) and are reported in Table I, above.
  • BIO-DOT Bio-Rad
  • the membrane was presoaked in Tris buffered saline consisting of 0.016M Tris HCl and 0.5M NaCl, pH 7.5 prior to its placement in the BIO-DOT (Bio-Rad) apparatus.
  • Tris buffered saline consisting of 0.016M Tris HCl and 0.5M NaCl, pH 7.5 prior to its placement in the BIO-DOT (Bio-Rad) apparatus.
  • One hundred ⁇ l of a 1 to 250 dilution of whole elementary bodies of DD-34 Chlamydial proteins inactivated with binary ethyleneamine was placed in each well and allowed to gravity flow through the membrane.
  • 200 ⁇ l of 1% bovine serum albumin in Tris buffered saline was allowed to gravity flow through the membrane to block any unbound sites.
  • the membrane was treated with 5 ⁇ g of biotinylated secondary antibody in Tris buffered saline containing 0.05% Tween 20 and agitated on a shaker platform for 30 minutes. This was followed by two washes with Tris buffered saline containing 0.05% Tween 20 and two washes with Tris buffered saline before being incubated in an avidin biotin complex for 30 minutes with gentle shaking. The membrane was washed two times with Tris buffered saline containing 0.05% Tween 20 and two times with Tris buffered saline. A diaminobenzidine plus nickel chloride substrate was added. After development, the reaction was stopped by washing with deionized distilled water.
  • Hybridoma 2-15 E3 produces monoclonal antibodies that identify strains of both Chlamydia psittaci and Chlamydia trachomatis isolates when tested by an enzyme linked immunosorbent assay and a nitrocellulose membrane dot blot assay.
  • the target polypeptide of 2-15 E3 was found to be in approximately the 96 kilodalton molecular weight range.
  • the hybridoma that secretes this monoclonal antibody was deposited on Aug. 28, 1991, under the conditions of the Budapest Treaty with the American Type Culture Collection, Rockville, Md., and has been assigned ATCC Accession No. HB10861.
  • the monoclonal antibody secreted by clone ATCC No. HB10861 was found to be able to detect a variety of Chlamydia psittaci strains: B577, 1PA, Borg, E58 (McNutt), CP-3, Texas Turkey, No. 1, Chlamydia trachomatis strains: TWAR 434, LGV--Type II all obtained from the American type culture collection and KSU89-3720, KSU88-15974 and KSU89-13400 isolated by Kansas State University. Other bacteria tested, however, had no cross reactivity: E. coli hemolytic, K88T, E. coli nonhemolytic, mucoid, E.
  • Electrophoresis was conducted as described by Laemmli (1970). Protein contents of 20 ⁇ g of C. psittaci strain DD-34, C. psittaci strain Borg, yolk sac membrane, chick embryo tissue and albumin were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis, transferred to 0.2 ⁇ nitrocellulose (American Bionetics, Inc., Hayward, Calif.) and Western blotted with monoclonal antibody 2-15 E3 and polyclonal antibodies to evaluate possible cross reactivity of the antibodies.
  • Electrophoresis sample buffer consisted of 0.121M Tris base, 0.001M ethylenediaminetetraacetate, 1% sodium dodecyl sulfate. Prior to loading, the gels were pre-run for 30 minutes at 10 ma constant current for each gel and electrophoresis was carried out at 30 ma constant current for each gel until proteins were near the bottom edge. The molecular weight marker lanes were removed and stained with a colloidal gold reagent (Jansens Auro Dye Forte protein stain, Olen, Belgium). The test proteins were probed with an immunoperoxidase system and a diaminobenzidine-nickle chloride substrate (Vector Laboratories, Burlingame, Calif.).
  • Chlamydial strains studied apparently share an antigenic epitope that is recognized by 2-15 E3 using an ELISA, and in the native or solubilized form when dot blotted to nitrocellulose; however, this epitope is persistent only in Borg after electrophoresis and transfer.
  • the antigenic polypeptide is apparently altered beyond recognition in strain DD-34 but persists in strain Borg; however, there appears to be enough reassociation of the solubilized proteins when dot blotted for the epitope to be recognized in strain DD-34 as well as Borg.
  • the 96 kilodalton protein of strain DD-34 appears from this study, to be a strong antigen.
  • the epitope recognized by 2-15 E3 has been shown to exist in both the binary ethyleneamine inactivated form and the noninactivated form.
  • polypeptides used in the vaccine trials were isolated by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Polypeptides ranging from a 40 to 140 kilodaltons of strain DD-34 were excised from the sodium dodecyl sulfate polyacrylamide gel electrophoresis, electroeluted and vacuum desiccated at room temperature to a reading of 446 on the dryness scale. These polypeptides were selected to provide support and adhesion for the antigenic 96 kilodalton polypeptide. The high degree of antigenicity and cross-reactivity of this polypeptide gives evidence of its ability to stimulate a strong immune response when purified and mixed with a suitable adjuvant. These polypeptides were rehydrated with RIBI adjuvant, MPL+TDM+CWS to make the test vaccine.
  • Three injections were given to four guinea pigs weighing approximately 700 g. These consisted of two injections of 0.2 cc given subcutaneously, in two different sites and one injection of 0.1 cc given intraperitoneally for a total of 1 mg protein.
  • the four vaccinated guinea pigs and one nonvaccinated guinea pig was challenged with guinea pigs inclusion conjunctivitis-vaginitis chlamydial elementary bodies (grown, isolated, and purified as previously described). This first challenge consisted of 0.1 ml intraocularly and 0.1 ml intravaginally. Another intranasal challenge was conducted three weeks after the first.
  • This challenge consisted of 0.15 ml of a respiratory strain of Chlamydia elementary bodies that were isolated from a bovine with pneumonia.
  • the guinea pigs were anesthetized with ether and 0.2 cc were injected into the right lung of each guinea pig using a 25 gauge, 1" needle.
  • the guinea pigs were subjected to a second challenge using a highly zoonotic parrot strain (DD-34) of Chlamydia.
  • the guinea pigs were again anesthetized with ether and 1 cc was injected into the right lung by hypodermic needle. This was expected to be a terminal challenge because of the pathogenicity of this agent.
  • All challenge materials consisted of approximately 10 mg of protein per ml. There were no clinical signs in any of the vaccinated guinea pigs--they continued the same pattern of food and water consumption.
  • the nonvaccinated guinea pig began to loose weight shortly after the first challenge, show severe respiratory signs, and symptoms of central nervous system disorders. All guinea pigs were euthanatized and necropsied. Tissues were taken and tested for chlamydial proteins using an enzyme-linked immunosorbent assay and an immunogold silver enhanced technique for tissues and secretions. Additionally, histopathological studies of tissue were documented. On gross pathology examination, the vaccinated guinea pigs showed no visible lesions. The right lung of the nonvaccinated guinea pig was blackened and apparently nonfunctional. Also, the plural cavity contained a large quantity of serofibrinous fluid. The pericardial sac also contained fibrinous fluid.
  • the uterus of the nonvaccinated guinea pig was enlarged, and darkened. Liver and lung tissues of all guinea pigs were examined by ELISA for chlamydial proteins using the 2-15 E3 monoclonal antibody described in Examples 2-5. The lungs of all guinea pigs were found to contain chlamydial proteins; however, only the nonvaccinated guinea pig contained chlamydial proteins in the liver. This was evidence that the Chlamydia challenge had become a systemic infection only in the nonvaccinated animal. The monoclonal antibody utilized in the ELISA will detect the 96 kilodalton polypeptide, even if the chlamydial elementary body has been destroyed by circulating antibodies or macrophages.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to a polypeptide vaccine and method to immunize subjects against Chlamydia. In particular, this invention relates to essentially pure polypeptides of Chlamydia psittaci strain DD-34 ranging from about 40 to 140 kilodaltons in a pharmaceutically acceptable carrier. These compositions are used to immunize several species of animals against Chlamydia. More specifically, this invention relates to the discovery of a highly immunogenic essentially pure polypeptide of Chlamydia psittaci strain DD-34 having a molecular weight of about 96 kilodaltons.

Description

BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to vaccines for veterinary use. In particular, it relates to Chlamydia vaccines useful for prevention and treatment of disease processes created or induced by Chlamydia organisms. In particular, this invention relates to essentially pure polypeptides of Chlamydia psittaci strain DD-34 in a pharmaceutically acceptable carrier and the use of this composition as a vaccine for a number of Chlamydia strains.
2. Description of the Prior Art
Chlamydia are unique organisms that infect a susceptible host by an infectious particle called an elementary body. An elementary body is small, approximately (200-300 nm) and is resistant to environmental factors. The organism attaches itself to the host cell and is ingested by a phagocytic process. Schachter, J., Overview of Chlamydia trachomatis Infection and Requirements for a Vaccine, Rev. Inf. Dis. 7:713 (1985).
Chlamydia are of medical and biological interest because of their unique interaction with eukaryotic host cells, and the diverse diseases they cause in man and animals. Blobel, H., T. Schlieber, Handbuch der bacteriellen Infection bei Tieren. Gustav Fisher Verlag Stuttgart, p. 447 (1985). Animals susceptible to Chlamydia psittaci infections are widely distributed in the animal kingdom, ranging from wild and domesticated birds and mammals to man. These infections have been identified as a cause of pneumonia, enteritis, encephalitis, conjunctivitis, and polyarthritis; abortions and genital disorders; and clinically unapparent infections. Blobel, H., T. Schlieber, Handbuch der bacteriellen Infection bei Tieren. Gustav Fisher Verlag Stuttgart, p. 447 (1985). Although Chlamydia psittaci is considered to be primarily a pathogen of animals other than man several strains have shown varying degrees of zoonotic potential. Filstein, M. R., Ley, A. B., Vernon, M. S., Goffney, A., Glickmen, L. T. Epidemic of Psittacosis in a College of Veterinary Medicine. Jour. of Vet. Med. p. 569-872 (Sep. 15, 1981). Fraiz, J. R., Jones, B., Chlamydial Infections. Ann. Rev. Med. 39:357-70 (1988). Fudge, A. M. Update on Chlamydiosis. Vet. Clin. of N. Amer. Small Animal Practice. 14(2):201-21 (March 1984). Johnson, F. W. A., Matheson, B. A., Williams, H., Laing, A. G., Jandial, V., Davidson-Lamb, R., Halliday, G. J., Hobson, D., Wong, S. Y., Hadley, K. M., Moffat, M. A. J., Poslethwaite, R. Abortion Due to Infection with Chlamydia psittaci in a Sheep Farmer's Wife. British Med. Jour. 290:592-94 (Feb. 23, 1985). Moran, R. Epidemiologic and Laboratory Observation of Chlamydia psittaci Infections in Pet Birds. Jour. of Amer. Vet. Med. Assn. 184(11):1372-4 (Jun. 1, 1984). Nagington, J. Psittacosis/Ornithosis in Cambridgeshire. 1975-1983. Jour. Hyg. Camb. 92:9-19. Yung, A. P., Grayson, M. L., Psittacosis--a Review of 135 Cases. The Med. Jour. of Australia 148:228-33 (Mar. 7, 1988). Favero, M. S., Biological Hazards in the Laboratory. Lab. Med., 18(10):665-70 (Oct. 1987). Filstein, M. R., Ley, A. B., Vernon, M. S., Goffney, A., Glickman, L. T. Epidemic of Psittacosis in a College of Veterinary Medicine. J. Vet. Med. p. 569-72 (Sep. 15, 1981). Fraiz, J. R., Jones, B. Chlamydial Infections. Ann. Rev. Med. 39:357-70 (1988).
Chlamydial infections are recognized in at least 130 species of birds and the transmission from birds to man is well documented. Various strains of Chlamydia psittaci are well recognized as causing disease syndromes in a wide variety of mammalian species and Chlamydia psittaci infections in humans have been epidemiologically linked to many of these sources. Fudge, A. M., Update on Chlamydiosis. Vet. Clin. of N. Amer. Small Animal Practice, 14(2):201-21 (March 1984). Moran, R., Epidemiologic and Laboratory Observation of Chlamydia psittaci Infections in Pet Birds. Jour. of Amer. Vet. Med. Assn. 184(11):1372-4 (Jun. 1, 1984). Nagington, J. Psittacosis/Ornithosis in Cambridgeshire. 1975-1983. Jour. Hyg. Camb. 92:9-19.
Vaccines against chlamydia have been disclosed. In particular, two proteins of molecular mass of 18,000 daltons and 31,000 daltons are known to be associated with infectious elementary bodies of C. trachomatis have been found to bind to eukaryotic cells. These proteins are thought to be of particular interest because the attachment of the pathogen to its host cell is critical to successful invasion of the elementary bodies. Antibodies raised against these proteins possess neutralizing activity, which may indicate a protective role for such antibodies. Purified 18 kilodalton C. trachomatis extra cellular binding protein substantially free of other C. trachomatis proteins in a pharmaceutically acceptable carrier and purified 31 kilodalton C. trachomatis extracellular binding protein substantially free of other C. trachomatis proteins in a pharmaceutically acceptable carrier have been disclosed as vaccines. EPA 0,293,079.
Previous molecular work with the subunits of Chlamydia biovars other than C. psittaci has, for the most part, been limited to a major outer membrane protein that has a molecular weight from 42 to 45 kilodaltons occupying 60 percent of the outer membrane and a 15 kilodaltons lipopolysaccharide that is known to be genus specific. Batteiger. B. E., Newhall V, W. J., Terho, P., Wilde III, C. E., Jones, R. B.: Antigenic Analysis of the Major Outer Membrane Protein of Chlamydia trachomatis with Murine Monoclonal Antibodies. Infect. Immun. 53(3)530-3 (1986). Bavoil, P., Ohlin, A., Schachter, J.: Role of Disulfide Bonding in Outer Membrane Structure and Permeability in Chlamydia trachomatis. Infect. Immun. 44(2):479-85 (1984). Brade, L., Schramek, S., Schade, U., Brade, H.: Chemical, Biological, and Immunochemical Properties of the Chlamydia psittaci Lipopolysaccharide. Infect. Immun. 54(2):568-74 (Nov. 1986). Caldwell, H. D., Judd, R. C.: Structural Analysis of Chlamydial Major Outer Membrane Proteins. Infect. Immun. 38:960-8 (Dec. 1982). Caldwell, H. D., Schachter, J.: Antigenic Analysis of the Major Outer Membrane Protein of Chlamydia spp. Infect. Immun. 35(3):1024-31 (Mar. 1982). Caldwell, H. D., Kromhout, J., Schachter, J.: Purification and Partial Characterization of the Major Outer Membrane Protein of Chlamydia trachomatis. Infect. Immun. 31(3):1161-76 (1981). Carlson, E. J., Peterson, E. M., de la Maza, L. M.: Cloning and Characterization of a Chlamydia trachomatis L3 DNA Fragment That Codes for an Antigenic Region of the Major Outer Membrane Protein and Specifically Hybridizes to the C- and C-Related-Complex Serovars. Infect. Immun. 57(2):487-94 (1989). Conlan, J. W., Clarke, I. N., Ward, M. E.: Epitope Mapping with Solid-Phase Peptides: Identification of Type-, Subspecies-, Species- and Genus-Reactive Antibody Binding Domains on the Major Outer Membrane Protein of Chlamydia trachomatis. Molecular Microbiology. 2(5):673-9 (1985). Ma, J. J., Chen, K. C. S., Kuo, C.: Identification of Conserved Regions for Species and Subspecies Specific Epitopes on the Major Outer Membrane Protein of Chlamydia trachomatis. Micro. Pathogenesis 3:299-307 (1987). Nano, F. E., Barstad, P. A., Mayer, L. W., Coligan, J. E., Caldwell, H. D.: Partial Amino Acid Sequence and Molecular Cloning of the Encoding Gene for the Major Outer Membrane Protein of Chlamydia trachomatis. Infect. Immun. 48(2):372-7 (1985). Pickett, M. A., Ward, M. E., Clarke, I. N.: High-level Expression and Epitope Localization of the Major Outer Membrane Protein of Chlamydia trachomatis Serovar L1. Molecular Microbiology. 2(5):681-5 (1988). Stephens, R. S., Wagar, E. A., Schoolnik, G. K.: High-Resolution Mapping of Serovar-Specific and Common Antigenic Determinants of the major Outer Membrane Protein of Chlamydia Trachomatis. J. Exp. Med. 167:817-31 (1988). Su, H., Zhang, Y., Barrera, O., Watkins, N. G., Caldwell, H. D.: Differential Effect of Trypsin on Infectivity of Chlamydia trachomatis: Loss of Infectivity Requires Clevage of Major Outer Membrane Protein Variable Domains II and IV. Infect. Immun. 56(8):2094-100 (1988). Tan, T., Herring, A. J., Anderson, I. E., Jones, G. E.: Protection of Sheep Against Chlamydia psittaci Infection with a Subcellular Vaccine Containing the Major Outer Membrane Protein. Infect. Immun. 58(8):3101-8 (1990). Taylor, H. R., Prendergast, R. A.: Attempted Oral Immunization with Chlamydial Lipopolysaccharide Subunit Vaccine. Invest. Ophthalmol. Vis. Sci. 28(10):1722-6 (Oct. 1987). Taylor, H. R., Prendergast, R. A.: Oral Immunization with Chlamydial Major Outer Membrane Protein (MOMP). Invest. Ophthalmol. Vis. Sci. 29(12):1847-53 (Dec. 1988). Zhang, Y., Stewart, S., Joseph, T., Taylor, H. R., Caldwell, H. D.: Protective Monoclonal Antibodies Recognize Epitopes Located on the Major Outer Membrane Protein of Chlamydia trachomatis1. J. Immun. 138:575-81 (1987). The above discussed work with the major outer membrane proteins, however, have not yet proven to be efficacious when utilized as a vaccine.
The polypeptide vaccine described in this application has shown, by an initial multiple challenge, to be highly protective against Chlamydia infection. Surprisingly, it was found that a 96 kilodalton polypeptide and certain associated polypeptides that includes the extracellular binding protein and other related proteins of ATCC strain DD-34 are highly antigenic and can provide protection from a variety of Chlamydia strains.
SUMMARY OF THE INVENTION
It is an object of this invention to make a polypeptide vaccine that protects several animal species against infection by Chlamydia. To achieve the objects of this invention and in accordance with the purposes of the present invention a 96 kilodalton polypeptide, of the Chlamydia psittaci strain DD-34 was isolated along with other polypeptides ranging in size from 40-140 kilodalton.
In particular, this invention is directed to a vaccine for treating patients to protect against a Chlamydia infection comprising administering an effective amount of a polypeptide as described herein above in a physiologically acceptable diluent. This invention further relates to a subunit vaccine against Chlamydia psittaci strain DD-34, wherein the polypeptides are reactive with antibodies secreted by hybridoma ATCC no. HB10861.
DETAILED DESCRIPTION OF THE INVENTION
Reference will now be made in detail to the presently preferred embodiments of the invention, which, together with the drawings and the following examples, serve to explain the principles of the invention.
As noted above, the present invention relates principally to a 96 kilodalton polypeptide, and to other polypeptides ranging from about 40 to 140 kilodaltons that are useful, for immunization against Chlamydia. In the examples, polypeptides ranging from 40 to 140 kilodaltons of strain DD-34 were used. It should be understood that in other embodiments the subunit vaccine may comprise the combination of the 42 and 96 kilodalton polypeptides and, in another embodiment the subunit vaccine may include only the 96 kilodalton polypeptide. It should be noted, however, that the molecular weights disclosed herein are not to be interpreted as absolute values.
The high degree of antigenicity and cross reactivity of these polypeptides gives evidence of their ability to stimulate a strong immune response when purified and mixed with a suitable adjuvant. Since this is a subunit vaccine it could be useful in several species of animals, and against several different biovars of chlamydia, without the delayed type hypersensitivity reaction or anamnestic responses reported with whole organism vaccines.
The polypeptides of the present invention are capable of forming "neutralizing antibodies" i.e. antibodies that will protect against Chlamydia psittaci and Chlamydia trachomatis in a variety of animals. In particular, the polypeptides have been found to be useful for immunizing against a bovine respiratory, DD-34, mouse pneumonitis, and guinea pig conjunctivitis strains of Chlamydia. Accordingly, the present invention is also directed to methods of protecting a patient against contracting Chlamydia psittaci and Chlamydia trachomatis.
The active component of the vaccine according to the invention can be employed with a physiologically acceptable diluent (medium), e.g. phosphate buffered saline. The vaccine may possibly be administered by subcutaneous, intradermal, intranasally or intramuscular injection, or as a water additive. Frequency of administration will vary depending upon the vaccine.
As a subunit vaccine, it is envisioned that the above described invention would afford protection to several species of animals such as mouse, guinea pig, cow and man. It is also expected to protect against several different biovars of Chlamydia, without the delayed type hypersensitivity reaction or anamnestic response reported with whole organism vaccines.
It should be understood that these specific antigenic epitopes can be made by recombinant DNA techniques or synthetic peptides. Baehr et al: Proc. Nat'l. Acad. Sci. USA 85:4000-4 (1988); Stephens et al.: J. Exp. Med. 167:817-31 (1988).
EXAMPLE 1 Hybridoma Production
Whole elementary bodies (ATCC No. VR854--Strain DD-34) were inactivated with a 1% solution of binary ethyleneamine at 37° C. for 24 hours (Larghi and Nebel, 1988; Larghi et al., 1976). Residual binary ethyleneamine was inactivated by a 1% solution of sodium thiosulfate (Larghi and Nebel, 1988; Larghi et al., 1976). One ml of inactivated elementary bodies containing 8.9 mg protein was mixed with 1 ml of physiological saline, added to a vial of RIBI adjuvant (ImmunoChem, Hamilton, Mont.) and warmed to 37° C. in a water bath prior to mouse inoculation.
Three-month old female Balb/C mice were injected intraperitoneally with 0.2 ml of the elementary body-adjuvant solution. One injection was given weekly for a total of three injections. A fourth injection without RIBI adjuvant was given intraperitoneally four days before fusion. The hyperimmunized spleen cells were fused with AG8 myeloma cells with the aid of polyethylene glycol. After four fusions and the production of approximately 1,600 hybridomas, 19 were identified as rapid growers. These 19 hybridomas were cloned when appropriate by limiting dilution.
EXAMPLE 2 Isotyping and Subisotyping Supernatants
Supernatants from the 19 hybridomas obtained in Example 1 were isotyped using an isotyping reagent kit (Hy Clone Laboratories, Logan, Utah) and subisotyped using a reagent kit (Calbiochem Corp., LaJolla, Calif.), according to the manufacturers' recommended protocols. Briefly, the supernatants were isotyped by coating 96-well microtiter plates with 100 μl of a plate coating solution containing 1% goat anti-mouse immunoglobulins. Excess solution was removed by tapping on absorbent paper before filling the wells with a phosphate-buffered saline-surfactant solution to reduce non-specific binding. Next, 50 μl of phosphate-buffered saline-surfactant and 50 μl of hybridoma supernatant was placed in the wells along with positive and negative controls. A peroxidase conjugate and a substrate composed of a concentrate of citrate buffer containing a 1% urea peroxide was used with O-phenylene diamine as a chromophobe.
For subisotyping, a plate coating solution containing 1% goat anti-mouse immunoglobulins was used to coat a 96-well microtiter plate. The supernatants were diluted with phosphate-buffered saline-surfactant solution and added to the plate. After washing, typing antisera was placed in the wells for testing the supernatants, and phosphate-buffered saline-surfactant was used for negative controls. A peroxidase conjugate was used followed by a 1% urea peroxide substrate and O-phenylene diamine as a chromophobe. The results of isotyping and subisotyping are reported in Table I, below.
              TABLE I                                                     
______________________________________                                    
Immunoglobulin types and assay reactions                                  
of the 19 monoclonal antibodies                                           
                 Dot blot assays                                          
                           Native   Solubilized                           
                           elementary                                     
                                    elementary                            
Clone    Isotype/          bodies   bodies                                
supernatants                                                              
         subisotype                                                       
                   ELISA   proteins proteins                              
______________________________________                                    
2-1 F10  IgM       -       -        -                                     
2-15 E3  IgG1      +       +        +                                     
2-11 F10 IgG1      +       -        -                                     
3-8 C8   IgM       weak +  -        -                                     
2-11 E9  IgG2a     weak +  -        -                                     
4-5 F3   IgG1, IgM +       -        -                                     
4-6 B6   IgM       +       -        -                                     
4-7 D10  IgM       +       -        -                                     
4-8 G11  IgG3, IgM weak +  -        -                                     
4-10 B8  IgM       weak +  -        -                                     
4-11 D8  IgG3      +       -        -                                     
4-12 B4  IgM       +       +        -                                     
4-12 B5  IgG3, IgM weak +  -        -                                     
4-14 B9  IgG3, IgM +       +        -                                     
4-14 D11 IgG1      weak +  -        -                                     
4-16 G3  IgM       weak +  -        -                                     
4-17 B2  IgG2b, IgM                                                       
                   +       -        -                                     
4-17 B8  IgG1, IgM -       -        -                                     
4-7 D10  IgM       weak +  -        -                                     
______________________________________
EXAMPLE 3 Enzyme Linked Immunosorbent Assay to Native Proteins
The hybridoma supernatants of Example 2 were further characterized by use of a mouse IgG, enzyme immunoassay, hybridoma screening kit according to the manufacturer's recommendations (Vector Laboratories, Burlingame, Calif.). Briefly, whole elementary bodies of C. psittaci strain DD-34 were diluted 1 to 250 in deionized distilled water and 100 μl was placed in each well of a 96-well microtiter plate (Midland Scientific, Inc., Omaha, Nebr.). Elementary bodies (ATCC No. VR854 Strain DD-34) were diluted 1 to 10 in a solution containing 0.218 molar sucrose, 0.0038M KH2 PO4, 0.0072M K2 HPO4, and 0.0049M phosphate glutamate sucrose. The phosphate glutamate sucrose solution had been autoclaved at 10 pound pressure for 10 minutes and the pH adjusted to 7.0 with 2N KOH prior to use. Yolk sacs of 7-day-old specific pathogen-free chicken eggs (Spafus, Inc., Roanoke, Ill.) were injected with 0.4 ml of the dilution of 1 to 10 elementary bodies-phosphate glutamate sucrose solution. Embryos that died within three days were discarded and assumed dead of bacterial contamination or trauma. Yolk sac membranes of all eggs that lived past three days were harvested on day seven, mixed with phosphate glutamate sucrose to make a 20% yolk sac membrane solution, homogenized and centrifuged at 300×G for 10 minutes at 4° C. The centrifugate contained three layers. The middle layer containing the elementary bodies was removed with a pipette and purified through RENOGRAFIN 60 (Squibb, New Brunswick, N.J.) density gradients, consisting of 22 ml of 20% RENOGRAFIN on top of 5 ml of 50% RENOGRAFIN. These gradients were centrifuged at 63,500×G for one hour at 4° C. The elementary body fraction collected at the 50% RENOGRAFIN (Squibb) interface. The elementary bodies were removed by drip fractionation and pelleted through calcium-magnesium-free phosphate-buffered saline by centrifuging at 49,200×G for 20 minutes at 4° C. Each pellet was resuspended in 1 ml of calcium-magnesium-free phosphate-buffered saline and frozen at -70° C.
The plate was sealed with cellophane tape and placed on a shaker in a 37° C. incubator overnight. Supernatants from each of the 19 hybridomas were diluted 1 to 250 and 100 μl of each was assayed in replicates of five. The assay was done using a biotinylated anti-mouse IgG in phosphate-buffered saline containing 1% normal bovine serum, followed by an avidin-enzyme system with a 2,2'azino-di (3-ethyl benthiazolin-sulfate) substrate. The results were read on a BIO-TEK EL-380 ELISA Reader at 405 nm (BIO-TEK, Winooski, Vt.) and are reported in Table I, above.
EXAMPLE 4 Dot Blot Assay with Native Chlamydial Proteins
A BIO-DOT (Bio-Rad) apparatus was used with a 0.2μ pore size nitrocellulose membrane. The membrane was presoaked in Tris buffered saline consisting of 0.016M Tris HCl and 0.5M NaCl, pH 7.5 prior to its placement in the BIO-DOT (Bio-Rad) apparatus. One hundred μl of a 1 to 250 dilution of whole elementary bodies of DD-34 Chlamydial proteins inactivated with binary ethyleneamine was placed in each well and allowed to gravity flow through the membrane. Next, 200 μl of 1% bovine serum albumin in Tris buffered saline was allowed to gravity flow through the membrane to block any unbound sites. This was followed by two washes with 200 μl of a solution consisting of Tris buffered saline containing 0.05% Tween 20. The supernatants from the 19 hybridomas were diluted 1 to 250 in an antibody solution consisting of 1% bovine serum albumin in Tris buffered saline containing 0.05% Tween 20. One hundred μl of each diluted supernatant was applied to the membrane in replicates of five and allowed to gravity flow. This was followed by three washes with Tris buffered saline containing 0.05% Tween 20. The membrane was removed from the apparatus and washed two more times in a glass dish with Tris buffered saline containing 0.05% Tween 20. Next, the membrane was treated with 5 μg of biotinylated secondary antibody in Tris buffered saline containing 0.05% Tween 20 and agitated on a shaker platform for 30 minutes. This was followed by two washes with Tris buffered saline containing 0.05% Tween 20 and two washes with Tris buffered saline before being incubated in an avidin biotin complex for 30 minutes with gentle shaking. The membrane was washed two times with Tris buffered saline containing 0.05% Tween 20 and two times with Tris buffered saline. A diaminobenzidine plus nickel chloride substrate was added. After development, the reaction was stopped by washing with deionized distilled water.
To insure enough protein to be recognized by the antibodies was sticking to the membrane, dilutions of 1 to 10 to 1 to 1,500 were run through a membrane and stained with Jansons Aurodye Forte protein stain (Bio-Tek, Winooski, Vt.). The results are reported in Table I, above.
EXAMPLE 5 Dot Blot Assay to Solubilized Proteins
The same protocol for the dot blot to native proteins was followed except the chlamydia elementary bodies were boiled for 10 minutes prior to running the assay. The results are reported in Table I, above. It is apparent from Table I that the only clone to recognize the Chlamydia elementary body proteins in all assays was 2-15 E3. This alone has been assigned ATCC No. HB10861. Out of four fusions and the production of approximately 1,600 hybridomas, 17 hybridoma supernatants reacted with varying degrees in the ELISA of Example 3 to whole chlamydial elementary bodies. After further screening, three supernatants bound to whole elementary bodies by both ELISA and dot blot to nitrocellulose, however, when the elementary bodies were solubilized by boiling for 10 minutes and dot blotted, only the supernatant from hybridoma 2-15 E3 reacted. Apparently, the epitope recognized by this monoclonal antibody was persistent after solubilization while the epitopes recognized by the other three monoclonal antibodies were destroyed or altered in such a way that they were no longer recognized.
Hybridoma 2-15 E3 produces monoclonal antibodies that identify strains of both Chlamydia psittaci and Chlamydia trachomatis isolates when tested by an enzyme linked immunosorbent assay and a nitrocellulose membrane dot blot assay. By sodium dodecyl sulfate polyacrylamide gel electrophoresis, the target polypeptide of 2-15 E3 was found to be in approximately the 96 kilodalton molecular weight range. The hybridoma that secretes this monoclonal antibody was deposited on Aug. 28, 1991, under the conditions of the Budapest Treaty with the American Type Culture Collection, Rockville, Md., and has been assigned ATCC Accession No. HB10861.
EXAMPLE 6 Reactivity Testing
The monoclonal antibody secreted by clone ATCC No. HB10861 was found to be able to detect a variety of Chlamydia psittaci strains: B577, 1PA, Borg, E58 (McNutt), CP-3, Texas Turkey, No. 1, Chlamydia trachomatis strains: TWAR 434, LGV--Type II all obtained from the American type culture collection and KSU89-3720, KSU88-15974 and KSU89-13400 isolated by Kansas State University. Other bacteria tested, however, had no cross reactivity: E. coli hemolytic, K88T, E. coli nonhemolytic, mucoid, E. coli nonhemolytic, nonmucoid, Pasteurella hemolytica, Pasteurella multocida, Moraxella sp., Klebsiella pneumoniae, Klebsiella bronchiseptica, Alcalgienes faecalis, Staphylococcus aureus, Streptococcus suis, Citrobacter sp., Acinetobacter lwoffi, Proteus mirabilis, Enterobacter cloacae, Enterobacter agglomerans, Pseudomonas aeruginosa, Salmonella sp., actinobacillus equuli, Actinobacillus, and Haemophilus.
It appears from these studies that the 96 kilodalton peptide contains an epitope common to various strains of Chlamydia in different animals.
EXAMPLE 7 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis and Immunoblotting of Strains, DD-34, Borg and Host Proteins
Electrophoresis was conducted as described by Laemmli (1970). Protein contents of 20 μg of C. psittaci strain DD-34, C. psittaci strain Borg, yolk sac membrane, chick embryo tissue and albumin were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis, transferred to 0.2μ nitrocellulose (American Bionetics, Inc., Hayward, Calif.) and Western blotted with monoclonal antibody 2-15 E3 and polyclonal antibodies to evaluate possible cross reactivity of the antibodies.
Electrophoresis sample buffer consisted of 0.121M Tris base, 0.001M ethylenediaminetetraacetate, 1% sodium dodecyl sulfate. Prior to loading, the gels were pre-run for 30 minutes at 10 ma constant current for each gel and electrophoresis was carried out at 30 ma constant current for each gel until proteins were near the bottom edge. The molecular weight marker lanes were removed and stained with a colloidal gold reagent (Jansens Auro Dye Forte protein stain, Olen, Belgium). The test proteins were probed with an immunoperoxidase system and a diaminobenzidine-nickle chloride substrate (Vector Laboratories, Burlingame, Calif.).
EXAMPLE 8 Western Blot of C. psittaci Strains DD-34 and Borg
The Western blotting showed that 2-15 E3, which reacted to solubilized proteins of C. psittaci DD-34 by dot blot, also probed for a 96 kilodalton protein of strain Borg; however, no probing was evident to the strain DD-34. Further blotting with a murine polyclonal antibody made to DD-34 whole elementary bodies also probed for the 96 kilodalton protein and faintly for a protein in the 60 kilodalton range of Borg with no probing for any of the DD-34 proteins.
Both Chlamydial strains studied apparently share an antigenic epitope that is recognized by 2-15 E3 using an ELISA, and in the native or solubilized form when dot blotted to nitrocellulose; however, this epitope is persistent only in Borg after electrophoresis and transfer. By linearization of the proteins in preparation for sodium dodecyl sulfate polyacrylamide gel electrophoresis, the antigenic polypeptide is apparently altered beyond recognition in strain DD-34 but persists in strain Borg; however, there appears to be enough reassociation of the solubilized proteins when dot blotted for the epitope to be recognized in strain DD-34 as well as Borg.
The 96 kilodalton protein of strain DD-34 appears from this study, to be a strong antigen. The epitope recognized by 2-15 E3 has been shown to exist in both the binary ethyleneamine inactivated form and the noninactivated form.
EXAMPLE 9 Vaccine Trials
The polypeptides used in the vaccine trials were isolated by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Polypeptides ranging from a 40 to 140 kilodaltons of strain DD-34 were excised from the sodium dodecyl sulfate polyacrylamide gel electrophoresis, electroeluted and vacuum desiccated at room temperature to a reading of 446 on the dryness scale. These polypeptides were selected to provide support and adhesion for the antigenic 96 kilodalton polypeptide. The high degree of antigenicity and cross-reactivity of this polypeptide gives evidence of its ability to stimulate a strong immune response when purified and mixed with a suitable adjuvant. These polypeptides were rehydrated with RIBI adjuvant, MPL+TDM+CWS to make the test vaccine.
Three injections were given to four guinea pigs weighing approximately 700 g. These consisted of two injections of 0.2 cc given subcutaneously, in two different sites and one injection of 0.1 cc given intraperitoneally for a total of 1 mg protein. Two weeks after the booster injection, the four vaccinated guinea pigs and one nonvaccinated guinea pig was challenged with guinea pigs inclusion conjunctivitis-vaginitis chlamydial elementary bodies (grown, isolated, and purified as previously described). This first challenge consisted of 0.1 ml intraocularly and 0.1 ml intravaginally. Another intranasal challenge was conducted three weeks after the first. This challenge consisted of 0.15 ml of a respiratory strain of Chlamydia elementary bodies that were isolated from a bovine with pneumonia. One week later, the guinea pigs were anesthetized with ether and 0.2 cc were injected into the right lung of each guinea pig using a 25 gauge, 1" needle. Three weeks later the guinea pigs were subjected to a second challenge using a highly zoonotic parrot strain (DD-34) of Chlamydia. The guinea pigs were again anesthetized with ether and 1 cc was injected into the right lung by hypodermic needle. This was expected to be a terminal challenge because of the pathogenicity of this agent. All challenge materials consisted of approximately 10 mg of protein per ml. There were no clinical signs in any of the vaccinated guinea pigs--they continued the same pattern of food and water consumption.
The nonvaccinated guinea pig began to loose weight shortly after the first challenge, show severe respiratory signs, and symptoms of central nervous system disorders. All guinea pigs were euthanatized and necropsied. Tissues were taken and tested for chlamydial proteins using an enzyme-linked immunosorbent assay and an immunogold silver enhanced technique for tissues and secretions. Additionally, histopathological studies of tissue were documented. On gross pathology examination, the vaccinated guinea pigs showed no visible lesions. The right lung of the nonvaccinated guinea pig was blackened and apparently nonfunctional. Also, the plural cavity contained a large quantity of serofibrinous fluid. The pericardial sac also contained fibrinous fluid. The uterus of the nonvaccinated guinea pig was enlarged, and darkened. Liver and lung tissues of all guinea pigs were examined by ELISA for chlamydial proteins using the 2-15 E3 monoclonal antibody described in Examples 2-5. The lungs of all guinea pigs were found to contain chlamydial proteins; however, only the nonvaccinated guinea pig contained chlamydial proteins in the liver. This was evidence that the Chlamydia challenge had become a systemic infection only in the nonvaccinated animal. The monoclonal antibody utilized in the ELISA will detect the 96 kilodalton polypeptide, even if the chlamydial elementary body has been destroyed by circulating antibodies or macrophages.
It will be appreciated that the instant specification and claims are set forth by way of illustration and not limitation, and that various modifications and changes may be made without departing from the spirit and scope of the present invention.

Claims (10)

I claim:
1. A subunit vaccine against Chlamydia infection comprising (1) a pharmaceutically acceptable carrier and (2) a polypeptide fraction of Chlamydia psittaci strain DD-34 consisting of polypeptides having molecular weights of between about 40 and 140 kilodaltons, said fraction comprising a polypeptide having a molecular weight of about 96 kilodaltons.
2. The vaccine of claim 1 wherein said polypeptide fraction consists of polypeptides having molecular weights of about 42 kilodaltons and about 96 kilodaltons.
3. A subunit vaccine against Chlamydia infection comprising (1) a pharmaceutically acceptable carrier and (2) a polypeptide having a molecular weight of about 96 kilodaltons from Chlamydia psittaci strain DD-34.
4. A subunit vaccine against Chlamydia infection consisting essentially of an isolated or purified polypeptide of Chlamydia psittaci strain DD-34 that is reactive with the antibody secreted by hybridoma ATCC No. HB10861.
5. The vaccine of any one of claims 1, 2, 3 or 4, further comprising an adjuvant.
6. A method of immunizing a subject against Chlamydia comprising administering an effective amount of the vaccine of claim 5.
7. A method of immunizing a subject against Chlamydia comprising administering an effective amount of the vaccine of claim 1.
8. A method of immunizing a subject against Chlamydia comprising administering an effective amount of the vaccine of claim 2.
9. A method of immunizing a subject against Chlamydia comprising administering an effective amount of the vaccine of claim 3.
10. A method of immunizing a subject against Chlamydia comprising administering an effective amount of the vaccine of claim 4.
US07/756,346 1991-09-06 1991-09-06 Polypeptides useful in prevention of chlamydia infection Expired - Fee Related US5725863A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/756,346 US5725863A (en) 1991-09-06 1991-09-06 Polypeptides useful in prevention of chlamydia infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/756,346 US5725863A (en) 1991-09-06 1991-09-06 Polypeptides useful in prevention of chlamydia infection

Publications (1)

Publication Number Publication Date
US5725863A true US5725863A (en) 1998-03-10

Family

ID=25043067

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/756,346 Expired - Fee Related US5725863A (en) 1991-09-06 1991-09-06 Polypeptides useful in prevention of chlamydia infection

Country Status (1)

Country Link
US (1) US5725863A (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017741A1 (en) * 1997-10-02 1999-04-15 Antex Biologics Inc. Chlamydia protein, gene sequence and uses thereof
US6355246B1 (en) 1999-06-10 2002-03-12 Board Of Trustees Of Michigan State University Feline calicivirus isolated from cat urine and vaccines thereof
US6447779B1 (en) * 1998-12-08 2002-09-10 Corixa Corporation Compounds for the diagnosis of Chlamydial infection
US20030021801A1 (en) * 2000-02-01 2003-01-30 Richard Stephens Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia
US6555115B1 (en) 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6605287B2 (en) 1997-08-28 2003-08-12 Board Of Supervisors Of Louisiana State University & Agricultural And Mechanical College Vaccines for Chlamydia psittaci infections
US6649370B1 (en) * 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US20040037846A1 (en) * 2000-10-02 2004-02-26 Jackson W. James Chlamydia pmp proteins, gene sequences and uses thereof
US20040137007A1 (en) * 2000-04-21 2004-07-15 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6919187B2 (en) 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US7105171B2 (en) 2002-03-07 2006-09-12 The Regents Of The University Of California Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
US20070031454A1 (en) * 2005-07-28 2007-02-08 Lowery David E Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus
US7390492B1 (en) 1999-09-02 2008-06-24 Board Of Trustees Of Michigan State University Vaccine to control equine protozoal myeloencephalitis in horses
US20080181918A1 (en) * 1998-12-08 2008-07-31 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US7419668B1 (en) 1999-09-02 2008-09-02 Board Of Trustees Of Michigan State University Vaccine to control equine protozoal myeloencephalitis in horses
US7537772B1 (en) 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118469A (en) * 1976-04-27 1978-10-03 Research Corporation Antigen for trachoma lymphogranuloma venereum (LGV) and non-gonococcal urethritis (NGU)
EP0017460A1 (en) * 1979-04-02 1980-10-15 Research Corporation Immunofluorescent test method and substance for use therein
US4267170A (en) * 1979-09-06 1981-05-12 Seawell Albert C Methods of using chlamydia vaccine for preventing and treating bovine diseases
US4271146A (en) * 1979-09-06 1981-06-02 Seawell Albert C Methods of using Chlamydia vaccine for preventing and treating bovine and ovine diseases
US4386065A (en) * 1981-02-11 1983-05-31 Research Corporation Vaccine against EAE
US4427782A (en) * 1981-03-03 1984-01-24 Caldwell Harlan D Isolation of principal outer membrane protein and antigen of Chlamydia trachomatis
US4497899A (en) * 1982-04-12 1985-02-05 Abbott Laboratories Immunoassay for Chlamydia trachomatis antigens
US4663291A (en) * 1984-07-06 1987-05-05 Becton, Dickinson And Company Method for solubilizing microbial protein obtained from Chlamydia trachomatis
WO1988000977A1 (en) * 1986-07-25 1988-02-11 Synergen, Inc. Polypeptides useful in diagnosis of mycoplasma infections in swine and recombinant-dna methods for manufacturing same
US4766065A (en) * 1984-08-23 1988-08-23 Becton Dickinson And Company Detection of cell membrane protein
EP0293079A2 (en) * 1987-04-24 1988-11-30 368800 Alberta Ltd Chlamydia vaccine
EP0348725A2 (en) * 1988-06-29 1990-01-03 Miles Inc. Species-specific epitode of chlamydia trachomatis and antibodies that recognize the same
US4916057A (en) * 1988-02-29 1990-04-10 Kallestad Diagnostics, Inc. Chlamydia assay employing base treatment
EP0363106A2 (en) * 1988-10-07 1990-04-11 Johnson & Johnson Clinical Diagnostics, Inc. Use of cationic surfactant to extract the chlamydial major outer membrane protein antigen

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118469A (en) * 1976-04-27 1978-10-03 Research Corporation Antigen for trachoma lymphogranuloma venereum (LGV) and non-gonococcal urethritis (NGU)
EP0017460A1 (en) * 1979-04-02 1980-10-15 Research Corporation Immunofluorescent test method and substance for use therein
US4267170A (en) * 1979-09-06 1981-05-12 Seawell Albert C Methods of using chlamydia vaccine for preventing and treating bovine diseases
US4271146A (en) * 1979-09-06 1981-06-02 Seawell Albert C Methods of using Chlamydia vaccine for preventing and treating bovine and ovine diseases
US4386065A (en) * 1981-02-11 1983-05-31 Research Corporation Vaccine against EAE
US4427782A (en) * 1981-03-03 1984-01-24 Caldwell Harlan D Isolation of principal outer membrane protein and antigen of Chlamydia trachomatis
US4497899A (en) * 1982-04-12 1985-02-05 Abbott Laboratories Immunoassay for Chlamydia trachomatis antigens
US4663291A (en) * 1984-07-06 1987-05-05 Becton, Dickinson And Company Method for solubilizing microbial protein obtained from Chlamydia trachomatis
US4766065A (en) * 1984-08-23 1988-08-23 Becton Dickinson And Company Detection of cell membrane protein
WO1988000977A1 (en) * 1986-07-25 1988-02-11 Synergen, Inc. Polypeptides useful in diagnosis of mycoplasma infections in swine and recombinant-dna methods for manufacturing same
EP0293079A2 (en) * 1987-04-24 1988-11-30 368800 Alberta Ltd Chlamydia vaccine
US4916057A (en) * 1988-02-29 1990-04-10 Kallestad Diagnostics, Inc. Chlamydia assay employing base treatment
EP0348725A2 (en) * 1988-06-29 1990-01-03 Miles Inc. Species-specific epitode of chlamydia trachomatis and antibodies that recognize the same
EP0363106A2 (en) * 1988-10-07 1990-04-11 Johnson & Johnson Clinical Diagnostics, Inc. Use of cationic surfactant to extract the chlamydial major outer membrane protein antigen

Non-Patent Citations (104)

* Cited by examiner, † Cited by third party
Title
Anderson et al., Efficacy Against Ovine Enzootic Abortin of an Experimental Vaccine Containing Purified Elementary Bodies of Chlamydia psittaci , Veterinary Microbiology 24:21 27 (1990). *
Anderson et al., Efficacy Against Ovine Enzootic Abortin of an Experimental Vaccine Containing Purified Elementary Bodies of Chlamydia psittaci, Veterinary Microbiology 24:21-27 (1990).
Baehr et al, Mapping Antigenic Domains Expressed by Chlamydia trachomatis Major Outer Membrane Protein Genes, Proc. Natl. Acad. Sci U.S.A. 85:4000 4004 (1988). *
Baehr et al, Mapping Antigenic Domains Expressed by Chlamydia trachomatis Major Outer Membrane Protein Genes, Proc. Natl. Acad. Sci U.S.A. 85:4000-4004 (1988).
Baghian et al, Antibody Response to Epitopes of Chlamydial Major Outer Membrane Proteins on Infectious Elementary Bodies and of the Reduced Polyacrylamide Gel Electrophoresis Separated Form, Infection and Immunity 58:1379 1383 (1990). *
Baghian et al, Antibody Response to Epitopes of Chlamydial Major Outer Membrane Proteins on Infectious Elementary Bodies and of the Reduced Polyacrylamide Gel Electrophoresis-Separated Form, Infection and Immunity 58:1379-1383 (1990).
Barron, Microbiology of Chlamydia. *
Batteiger et al., Antigenic Analysis of the Major Outer Membrane Protein of Chlamydia trachomatis with Murine Monoclonal Antibodies, Infectino and Immunity 53:530 533 (1986). *
Batteiger et al., Antigenic Analysis of the Major Outer Membrane Protein of Chlamydia trachomatis with Murine Monoclonal Antibodies, Infectino and Immunity 53:530-533 (1986).
Bavoil et al., Role of Disulfide Bonding in Outer Membrane Structure and Permeability in Chlamydia trachomatis , Infection and Immunity 44:479 485 (1984). *
Bavoil et al., Role of Disulfide Bonding in Outer Membrane Structure and Permeability in Chlamydia trachomatis, Infection and Immunity 44:479-485 (1984).
Blobel et al., Chlamydia, Handbuch der Bakteriellen Infektionen bei Tieren, Band V. 447 531 (1985). *
Blobel et al., Chlamydia, Handbuch der Bakteriellen Infektionen bei Tieren, Band V. 447-531 (1985).
Brade et al., Chemical, Biological, and Innunochemical Properties of the Chlamydia psittaci Lipoplysaccharide, Infection and Immunity 54:568 574 (1986). *
Brade et al., Chemical, Biological, and Innunochemical Properties of the Chlamydia psittaci Lipoplysaccharide, Infection and Immunity 54:568-574 (1986).
Caldwell et al., Antigen Analysis of the Major Outer Membrane Protein of Chlamydia spp., Infection and Immunity 35:1024 1031 (1982). *
Caldwell et al., Antigen Analysis of the Major Outer Membrane Protein of Chlamydia spp., Infection and Immunity 35:1024-1031 (1982).
Caldwell et al., Structural Analysis of Chlamydial Major Outer Membrane Proteins, Infection and Immunity 38:960 968 (1982). *
Caldwell et al., Structural Analysis of Chlamydial Major Outer Membrane Proteins, Infection and Immunity 38:960-968 (1982).
Carlson et al., Cloning and Characterization of a Chlamydia trachomatis L3 DNA Fragment That Codes for an Antigenic Region of the Major Outer Membrane Protein and Specifically Hybridizes to the C and C Related Complex Serovars, Infection and Immunity 57:487 494 (1989). *
Carlson et al., Cloning and Characterization of a Chlamydia trachomatis L3 DNA Fragment That Codes for an Antigenic Region of the Major Outer Membrane Protein and Specifically Hybridizes to the C-and C-Related-Complex Serovars, Infection and Immunity 57:487-494 (1989).
Chandler et al. I, A New Enzyme Immunoassay System Suitable for Field Use and Its Application in a Snake Venom Detection Kit, Clinica Chimica Acta 121:225 230 (1982). *
Chandler et al. I, A New Enzyme Immunoassay System Suitable for Field Use and Its Application in a Snake Venom Detection Kit, Clinica Chimica Acta 121:225-230 (1982).
Chandler et al. II, An Investigation of the Use of Urease Antibody Conjugates in Enzyme Immunoassays, J. of Immunological Methods 53:187 194 (1982). *
Chandler et al. II, An Investigation of the Use of Urease-Antibody Conjugates in Enzyme Immunoassays, J. of Immunological Methods 53:187-194 (1982).
Conlan et al. I, Epitope Mapping with Solid Phase Peptides: Identification of Type , Subspecies , Species and Genus Reactive Antibody Binding Domains on the Major Outer Membrane Protein of Chlamydia trachomatis , Molecular Microbiology 2(5):673 679 (1988). *
Conlan et al. I, Epitope Mapping with Solid-Phase Peptides: Identification of Type-, Subspecies-, Species-and Genus-Reactive Antibody Binding Domains on the Major Outer Membrane Protein of Chlamydia trachomatis, Molecular Microbiology 2(5):673-679 (1988).
Conlan et al. II, The major outer membrane protein of Chlamydia trachomatis : critical binding site and conformation determine the specificity of antibody binding to viable chlamydiae, Molecular Microbiology 3(3):311 318 (1989). *
Conlan et al. II, The major outer membrane protein of Chlamydia trachomatis: critical binding site and conformation determine the specificity of antibody binding to viable chlamydiae, Molecular Microbiology 3(3):311-318 (1989).
Dopfer et al., Vertraglichkeits und immunisierungsversuche mit einer kommerziellen Vakzine gegen Chlamydia psittaci und Coxiella burnetii , Dtsch. tierarztl. Wschr. 93:267 269 (1986). *
Dopfer et al., Vertraglichkeits-und immunisierungsversuche mit einer kommerziellen Vakzine gegen Chlamydia psittaci und Coxiella burnetii, Dtsch. tierarztl. Wschr. 93:267-269 (1986).
Favero, Biological Hazards in the Laboratory, Laboratory Medicine 18:665 670 (1987). *
Favero, Biological Hazards in the Laboratory, Laboratory Medicine 18:665-670 (1987).
Filstein et al., Epidemic of Psittacosis in a College of Veterinary Medicine, JAVMA 179:569 572 (1981). *
Filstein et al., Epidemic of Psittacosis in a College of Veterinary Medicine, JAVMA 179:569-572 (1981).
Fraiz et al., Chlamydial Infectios, Am. Rev. Med. 39:357 370 (1988). *
Fraiz et al., Chlamydial Infectios, Am. Rev. Med. 39:357-370 (1988).
Fudge, Update on Chlamydiosis, Veterinary Clinics of North America: Small Animal Practice 14:201 221 (1984). *
Fudge, Update on Chlamydiosis, Veterinary Clinics of North America: Small Animal Practice 14:201-221 (1984).
Johnson et al. I, Abortion due to infection with Chlamydia psittaci in a sheep farmer s wife, British Medical Journal 290:592 595 (1985). *
Johnson et al. I, Abortion due to infection with Chlamydia psittaci in a sheep farmer's wife, British Medical Journal 290:592-595 (1985).
Johnson et al. II, Intracerebral Infection of Mice with Ovine Strains of Chlamydia psittaci : an Animal Screening Test for the Assay of Vaccines, J. Comp. Path. 96:497 505 (1986). *
Johnson et al. II, Intracerebral Infection of Mice with Ovine Strains of Chlamydia psittaci: an Animal Screening Test for the Assay of Vaccines, J. Comp. Path. 96:497-505 (1986).
Kuo et al., Ultrascrutural Study of Chlamydia trachomatis Surface Antigens by Immunogold Staining with Monoclonal Antibodies, Infection and Immunity 55: 1324 1328 (1987). *
Kuo et al., Ultrascrutural Study of Chlamydia trachomatis Surface Antigens by Immunogold Staining with Monoclonal Antibodies, Infection and Immunity 55: 1324-1328 (1987).
Lagrange et al., Vaccines against Mycobacteria and Other Intracellular Multiplying Bacteria, Ann. Inst. Pasteur/Immunol. 136:151 162 (1985). *
Lagrange et al., Vaccines against Mycobacteria and Other Intracellular Multiplying Bacteria, Ann. Inst. Pasteur/Immunol. 136:151-162 (1985).
Larghi et al. I, Ethylenimine Inactivated Rabies Vaccine of Tissue Culture Origin, J. Clin. Microbiology 3:26 33 (1967). *
Larghi et al. I, Ethylenimine-Inactivated Rabies Vaccine of Tissue Culture Origin, J. Clin. Microbiology 3:26-33 (1967).
Larghi et al. II, Rabies Virus Inactivation by Binary Ethylenimine: New Method for Inactivated Vaccine Production, J. Clin. Microbiology 11:120 122 (1980). *
Larghi et al. II, Rabies Virus Inactivation by Binary Ethylenimine: New Method for Inactivated Vaccine Production, J. Clin. Microbiology 11:120-122 (1980).
Ma et al., Identification of conserved regions for species and subspecies specific epitopes on the major outer membrane protein of Chlamydia trachomatis , Microbial Pathogenesis 3:299 307 (1987). *
Ma et al., Identification of conserved regions for species and subspecies specific epitopes on the major outer membrane protein of Chlamydia trachomatis, Microbial Pathogenesis 3:299-307 (1987).
MacDonald, Antigens of Chlamydia trachomatis , Reviews of Infectious Diseases 7:731 736 (1985). *
MacDonald, Antigens of Chlamydia trachomatis, Reviews of Infectious Diseases 7:731-736 (1985).
Mahajan et al., Development of a Macromolecular Vaccine against Experimental Chlamydiosis and Berberine a new anti trachoma agent., 103 109 (1985). *
Mahajan et al., Development of a Macromolecular Vaccine against Experimental Chlamydiosis and Berberine--a new anti-trachoma agent., 103-109 (1985).
Mohan, Epidemiologic and laboratory observations of Chlamydia psittaci infection in pet birds, JAVMA 184:1372 1374 (1984). *
Mohan, Epidemiologic and laboratory observations of Chlamydia psittaci infection in pet birds, JAVMA 184:1372-1374 (1984).
Moulder, The relation of the Psittacosis Group (Chlamydiae) to Bacteria and Viruses, Annual Review of Microbiology 20:107 130 (1966). *
Moulder, The relation of the Psittacosis Group (Chlamydiae) to Bacteria and Viruses, Annual Review of Microbiology 20:107-130 (1966).
Nagington, Psittacosis/ornithosis in Cambridgeshire 1975 1983, J. Hyg., Camb. 92:9 19 (1984). *
Nagington, Psittacosis/ornithosis in Cambridgeshire 1975-1983, J. Hyg., Camb. 92:9-19 (1984).
Nano et al., Partial Amino Acid Sequence and Molecular Cloning of the Encoding Gene for the Major Outer Membrane Protein of Chlamydia trachomatis , Infjection and Immunity 48:372 377 (1985). *
Nano et al., Partial Amino Acid Sequence and Molecular Cloning of the Encoding Gene for the Major Outer Membrane Protein of Chlamydia trachomatis, Infjection and Immunity 48:372-377 (1985).
Puy et al., Immunological specificity of monoclonal antibodies to Chlamydia psittaci ovine abortion strain, Immunology Letters 23:217 222 (1989/1990). *
Puy et al., Immunological specificity of monoclonal antibodies to Chlamydia psittaci ovine abortion strain, Immunology Letters 23:217-222 (1989/1990).
Rank et al., Protective Role of Serum Antibody in Immunity to Chlamydial Genital Infection, Infection Immunity 57:299 301 (1989). *
Rank et al., Protective Role of Serum Antibody in Immunity to Chlamydial Genital Infection, Infection Immunity 57:299-301 (1989).
Schachter, Overview of Chlamydia trachomatis Infection and the Requirements for a Vaccine, Reviews of Infectious Diseases 7:713 716 (1985). *
Schachter, Overview of Chlamydia trachomatis Infection and the Requirements for a Vaccine, Reviews of Infectious Diseases 7:713-716 (1985).
Seki et al., Monoclonal Antibodies to Chlamydia psittaci : Characteristics and Antigenic Analysis, Jpn. J. Vet Sci. 50:383 393 (1988). *
Seki et al., Monoclonal Antibodies to Chlamydia psittaci: Characteristics and Antigenic Analysis, Jpn. J. Vet Sci. 50:383-393 (1988).
Smith et al., A modified ELISA that selectively detects monoclonal antibodies recognizing native antigen, J. of Immunological Methods 94:31 35 (1986). *
Smith et al., A modified ELISA that selectively detects monoclonal antibodies recognizing native antigen, J. of Immunological Methods 94:31-35 (1986).
Stephens et al. I, A species specific major outer membrane protein domain, 110 113. *
Stephens et al. I, A species-specific major outer membrane protein domain, 110-113.
Stephens et al. II, High Resolution Mapping of Serovar Specific and Common Antigenic Determinants of the Major Outer Membrane Protein of Chlamydia trachomatis , J. Exp. Med. 167:817 831 (1988). *
Stephens et al. II, High-Resolution Mapping of Serovar-Specific and Common Antigenic Determinants of the Major Outer Membrane Protein of Chlamydia trachomatis, J. Exp. Med. 167:817-831 (1988).
Storz, Chlamydia and Chlamydia Induced Diseases (Charles C. Thomas Publishers 1971). *
Storz, Chlamydia and Chlamydia-Induced Diseases (Charles C. Thomas Publishers 1971).
Su et al., Differential Effect of Trypsin on Infectivity of Chlamydia trachomatis : Loss of Infectivity Requires Cleavage of Major Outer Membrane Protein Variable Domains II and IV, Infection and Immunity 56:2094 2100 (1988). *
Su et al., Differential Effect of Trypsin on Infectivity of Chlamydia trachomatis: Loss of Infectivity Requires Cleavage of Major Outer Membrane Protein Variable Domains II and IV, Infection and Immunity 56:2094-2100 (1988).
Tan et al., Protection of Sheep against Chlamydia psittaci Infection with a Subcellular Vaccine Containing the Major Outer Membrane Protein, Infection and Immunity 58:3101 3108 (1990). *
Tan et al., Protection of Sheep against Chlamydia psittaci Infection with a Subcellular Vaccine Containing the Major Outer Membrane Protein, Infection and Immunity 58:3101-3108 (1990).
Taylor et al. I, Attempted Oral Immunization with Chlamydial Lipopolysaccharide Subunit Vaccine, Investigative Ophthalmology & Visual Science 28:1722 1726 (1987). *
Taylor et al. I, Attempted Oral Immunization with Chlamydial Lipopolysaccharide Subunit Vaccine, Investigative Ophthalmology & Visual Science 28:1722-1726 (1987).
Taylor et al. II, Oral Immunization with Chlamydial Major Outer Membrane Protein (MOMP), Investigative Ophthalmology & Visual Science 29:1847 1853 (1988). *
Taylor et al. II, Oral Immunization with Chlamydial Major Outer Membrane Protein (MOMP), Investigative Ophthalmology & Visual Science 29:1847-1853 (1988).
Toyofuku et al., Monoclonal Antibodies against Chlamydia psittaci , Microbiol. Immunol. 30:945 955 (1986). *
Toyofuku et al., Monoclonal Antibodies against Chlamydia psittaci, Microbiol. Immunol. 30:945-955 (1986).
U.S. application No. 07/324,664, Caldwell et al., filed Mar. 17, 1989. *
Wenman et al., Chlamydia trachomatis Elementary Bodies Possess Proteins which Bind to Eucaryotic Cell Membranes, J. Bacteriology 165:602 607 (1986). *
Wenman et al., Chlamydia trachomatis Elementary Bodies Possess Proteins which Bind to Eucaryotic Cell Membranes, J. Bacteriology 165:602-607 (1986).
Yung et al., Psittacosis a review of 135 cases, The Medical Journal of Australia 148:228 233 (1988). *
Yung et al., Psittacosis--a review of 135 cases, The Medical Journal of Australia 148:228-233 (1988).
Zhang et al. I, Protective Monoclonal Antibodies Recognize Epitopes Located on the Major Outer Membrane Protein of Chlamydia trachomatis , J. Immunology 138:575 581 (1987). *
Zhang et al. I, Protective Monoclonal Antibodies Recognize Epitopes Located on the Major Outer Membrane Protein of Chlamydia trachomatis, J. Immunology 138:575-581 (1987).
Zhang et al: II, The Low Molecular Mass, Cysteine Rich Outer Membrane Protein of Chlamydia trachomatis Possesses Both Biovar and Species Specific Epitopes, Infection and Immunity 55:2570 2573 (1987). *
Zhang et al: II, The Low-Molecular-Mass, Cysteine-Rich Outer Membrane Protein of Chlamydia trachomatis Possesses Both Biovar-and Species-Specific Epitopes, Infection and Immunity 55:2570-2573 (1987).
Zhong et al. I, Immunaccessible Peptide Sequences of the Major Outer Membrane Protein from Chlamydia trachomatis Serovar C, Infection and Immunity 58:3438 3441 (1990). *
Zhong et al. I, Immunaccessible Peptide Sequences of the Major Outer Membrane Protein from Chlamydia trachomatis Serovar C, Infection and Immunity 58:3438-3441 (1990).
Zhong et al. II, Mapping Antigenic Sites on the Outer Membrane Protein of Chlamydia trachomatis with Synthetic Peptides, Infection and Immunity 58:1450 1455 (1990). *
Zhong et al. II, Mapping Antigenic Sites on the Outer Membrane Protein of Chlamydia trachomatis with Synthetic Peptides, Infection and Immunity 58:1450-1455 (1990).

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605287B2 (en) 1997-08-28 2003-08-12 Board Of Supervisors Of Louisiana State University & Agricultural And Mechanical College Vaccines for Chlamydia psittaci infections
US7279171B2 (en) 1997-08-28 2007-10-09 Board Of Supervisors Of Louisiana State University And Mechanical College Vaccines for Chlamydia psittaci infections
US20050037019A1 (en) * 1997-08-28 2005-02-17 Kousoulas Konstantin G. Vaccines for Chlamydia psittaci infections
US6642023B1 (en) 1997-10-02 2003-11-04 Antex Biologics, Inc Chlamydia protein, gene sequence and uses thereof
US6887843B1 (en) 1997-10-02 2005-05-03 Antex Biologics, Inc. Chlamydia protein, gene sequence and uses thereof
US7419807B2 (en) 1997-10-02 2008-09-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and uses thereof
WO1999017741A1 (en) * 1997-10-02 1999-04-15 Antex Biologics Inc. Chlamydia protein, gene sequence and uses thereof
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
US7534445B2 (en) 1997-10-02 2009-05-19 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
US20040067524A1 (en) * 1997-10-02 2004-04-08 Antex Biologics Inc. Chlamydia protein, gene sequence and uses thereof
US20040137005A1 (en) * 1997-10-02 2004-07-15 Antex Biologics, Inc. Chlamydia protein, sequence and uses thereof
US7655246B2 (en) 1997-10-02 2010-02-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and uses thereof
US20050048557A1 (en) * 1997-10-02 2005-03-03 Jackson W. James Chlamydia protein, gene sequence and uses thereof
US6649370B1 (en) * 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6447779B1 (en) * 1998-12-08 2002-09-10 Corixa Corporation Compounds for the diagnosis of Chlamydial infection
US6555115B1 (en) 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20110142872A1 (en) * 1998-12-08 2011-06-16 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US8052975B2 (en) 1998-12-08 2011-11-08 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20090035296A1 (en) * 1998-12-08 2009-02-05 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US7462357B2 (en) 1998-12-08 2008-12-09 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20080299142A1 (en) * 1998-12-08 2008-12-04 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US8263089B2 (en) 1998-12-08 2012-09-11 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20080181918A1 (en) * 1998-12-08 2008-07-31 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6355246B1 (en) 1999-06-10 2002-03-12 Board Of Trustees Of Michigan State University Feline calicivirus isolated from cat urine and vaccines thereof
US7390492B1 (en) 1999-09-02 2008-06-24 Board Of Trustees Of Michigan State University Vaccine to control equine protozoal myeloencephalitis in horses
US7419668B1 (en) 1999-09-02 2008-09-02 Board Of Trustees Of Michigan State University Vaccine to control equine protozoal myeloencephalitis in horses
US7510720B1 (en) 1999-09-02 2009-03-31 Board Of Trustees Of Michigan State University Vaccine to control equine protozoal myeloencephalitis in horses
US6899880B2 (en) 2000-02-01 2005-05-31 The Regents Of The University Of California Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia
US20030021801A1 (en) * 2000-02-01 2003-01-30 Richard Stephens Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia
US20050266016A1 (en) * 2000-02-01 2005-12-01 Richard Stephens Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
US8105607B2 (en) 2000-02-01 2012-01-31 The Regents Of The University Of California Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
US20090047283A1 (en) * 2000-04-21 2009-02-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20040137007A1 (en) * 2000-04-21 2004-07-15 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20080199456A1 (en) * 2000-04-21 2008-08-21 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20050232941A1 (en) * 2000-04-21 2005-10-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6919187B2 (en) 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US7384638B2 (en) 2000-04-21 2008-06-10 Corixa Corporation Compounds and methods for treatment and diagnosis of Chlamydial infection
US20040037846A1 (en) * 2000-10-02 2004-02-26 Jackson W. James Chlamydia pmp proteins, gene sequences and uses thereof
US20070292437A1 (en) * 2000-10-02 2007-12-20 Emergent Product Development Gaithersburg Inc. Chlamydia PMP Proteins, Gene Sequences and Uses Thereof
US7803388B2 (en) 2000-10-02 2010-09-28 Emergent Product Development Gaithersburg, Inc. Chlamydia PMP proteins, gene sequences and uses thereof
US20070292425A1 (en) * 2000-10-02 2007-12-20 Emergent Product Development Gaithersburg Inc. Chlamydia PMP Proteins, Gene Sequences and Uses Thereof
US7537772B1 (en) 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
US7851609B2 (en) 2000-10-02 2010-12-14 Emergent Product Development Gaithersburg Inc. Chlamydia PMP proteins, gene sequences and uses thereof
US7731980B2 (en) 2000-10-02 2010-06-08 Emergent Product Development Gaithersburg Inc. Chlamydia PMP proteins, gene sequences and uses thereof
US20060233826A1 (en) * 2002-03-07 2006-10-19 Stephens Richard S Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
US7253275B2 (en) 2002-03-07 2007-08-07 The Regents Of The University Of California Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
US20100189738A1 (en) * 2002-03-07 2010-07-29 Stephens Richard S PORIN B (PorB) AS A THERAPEUTIC TARGET FOR PREVENTION AND TREATMENT OF INFECTION BY CHLAMYDIA
US7670855B2 (en) 2002-03-07 2010-03-02 The Regents Of The University Of California Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
US8679510B2 (en) 2002-03-07 2014-03-25 The Regents Of The University Of California Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
US8337866B2 (en) 2002-03-07 2012-12-25 The Regents Of The University Of California Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia
US7105171B2 (en) 2002-03-07 2006-09-12 The Regents Of The University Of California Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
US8025891B2 (en) 2002-03-07 2011-09-27 The Regents Of The University Of California Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
US20080199474A1 (en) * 2002-03-07 2008-08-21 Stephens Richard S Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
US20070031454A1 (en) * 2005-07-28 2007-02-08 Lowery David E Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus
US7790169B2 (en) 2005-07-28 2010-09-07 Pfizer Inc. Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus
EP2292250A1 (en) 2005-07-28 2011-03-09 Pfizer Products Inc. Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline parvovirus and feline herpes virus
US8444997B2 (en) 2005-07-28 2013-05-21 Zoetis Llc Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus
US20110052619A1 (en) * 2005-07-28 2011-03-03 Pfizer Inc. Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus

Similar Documents

Publication Publication Date Title
US5725863A (en) Polypeptides useful in prevention of chlamydia infection
Pei et al. Purification and characterization of a family of high molecular weight surface-array proteins from Campylobacter fetus.
Svennerholm et al. Monoclonal antibodies against Escherichia coli heat-stable toxin (STa) and their use in a diagnostic ST ganglioside GM1-enzyme-linked immunosorbent assay
Hu et al. A Mycoplasma genitalium protein resembling the Mycoplasma pneumoniae attachment protein
Musher et al. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection?
Van Zijderveld et al. Comparison of four different enzyme-linked immunosorbent assays for serological diagnosis of Salmonella enteritidis infections in experimentally infected chickens
Matthews et al. The application of epitope mapping in the development of a new serological test for systemic candidosis
US5470958A (en) Antisera against a PEB1 antigen from Campylobacter jejuni
IE59741B1 (en) Monoclonal antibodies cross-reactive and cross-protective against p. aeruginosa serotypes
GB2307987A (en) Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto
US6040148A (en) Corynebacterial stress proteins
Watson Evaluation of attenuated, live staphylococcal mastitis vaccine in lactating heifers
Wren et al. Antigenic cross-reactivity and functional inhibition by antibodies to Clostridium difficile toxin A, Streptococcus mutans glucan-binding protein, and a synthetic peptide
Ikemori et al. Research note: avidity of chicken yolk antibodies to enterotoxigenic Escherichia coli fimbriae
US5212062A (en) Method and composition to direct Chlamydia psittaci or Chlamydia trachomatis infection
Gogolewski et al. Protective ability of antibodies against 78-and 40-kilodalton outer membrane antigens of Haemophilus somnus
Lepper Vaccination against infectious bovine keratoconjunctivitis: protective efficacy and antibody response induced by pili of homologous and heterologous strains of Moraxella bovis
EP0690724A1 (en) Chlamydia vaccine and process
Cimolai et al. Immunological cross-reactivity of a Mycoplasma pneumoniae membrane-associated protein antigen with Mycoplasma genitalium and Acholeplasma laidlawii
Lee et al. Sialoglycoprotease of Pasteurella haemolytica A1: detection of antisialoglycoprotease antibodies in sera of calves
Qu et al. Characterization of a neutralizing monoclonal antibody directed at variable domain I of the major outer membrane protein of Chlamydia trachomatis C-complex serovars
Baghian et al. Antibody response to epitopes of chlamydial major outer membrane proteins on infectious elementary bodies and of the reduced polyacrylamide gel electrophoresis-separated form
Kothary et al. Purification and characterization of a Chinese hamster ovary cell elongation factor of Vibrio hollisae
Bailey et al. Production of murine monoclonal antibodies to the major axial filament polypeptide of Treponema pallidum
Barthe et al. Common epitope on the lipopolysaccharide of Legionella pneumophila recognized by a monoclonal antibody

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNITED STATES OF AMERICA, THE, AS REPRESENTED BY T

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:DANIELS, EDDIE K.;WOOLLEN, NEAL E.;REEL/FRAME:005903/0637

Effective date: 19910924

REMI Maintenance fee reminder mailed
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

SULP Surcharge for late payment
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20060310